Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 1,051–1,060 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1051

    Medicine slug
    bulevirtide-gmod
    Medicine name
    Bulevirtide-Gmod
    Enzyme or transporter
    OCT1
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:12391cc2-38c2-4cf5-86d3-2be9370127fc (opens source in a new tab)

      Bulevirtide-Gmod label

      Version not recorded · Effective date not recorded

      Transporter Systems: In vitro studies have shown that no clinically relevant interactions are expected for efflux transporters including MDR1, BCRP, BSEP, MATE1, and MATE2K and uptake transporters including OATP2B1, OAT1, OAT3, OCT1, and OCT2.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:12391cc2-38c2-4cf5-86d3-2be9370127fc (opens source in a new tab)

      Bulevirtide-Gmod label

      Version not recorded · Effective date not recorded

      Transporter Systems: In vitro studies have shown that no clinically relevant interactions are expected for efflux transporters including MDR1, BCRP, BSEP, MATE1, and MATE2K and uptake transporters including OATP2B1, OAT1, OAT3, OCT1, and OCT2.

  2. Projected row 1052

    Medicine slug
    bulevirtide-gmod
    Medicine name
    Bulevirtide-Gmod
    Enzyme or transporter
    OCT2
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:12391cc2-38c2-4cf5-86d3-2be9370127fc (opens source in a new tab)

      Bulevirtide-Gmod label

      Version not recorded · Effective date not recorded

      Transporter Systems: In vitro studies have shown that no clinically relevant interactions are expected for efflux transporters including MDR1, BCRP, BSEP, MATE1, and MATE2K and uptake transporters including OATP2B1, OAT1, OAT3, OCT1, and OCT2.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:12391cc2-38c2-4cf5-86d3-2be9370127fc (opens source in a new tab)

      Bulevirtide-Gmod label

      Version not recorded · Effective date not recorded

      Transporter Systems: In vitro studies have shown that no clinically relevant interactions are expected for efflux transporters including MDR1, BCRP, BSEP, MATE1, and MATE2K and uptake transporters including OATP2B1, OAT1, OAT3, OCT1, and OCT2.

  3. Projected row 1053

    Medicine slug
    buprenorphine
    Medicine name
    Buprenorphine
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    8
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Effect of CYP3A4 Inhibitors In a drug-drug interaction study, buprenorphine transdermal system 10 mcg/hour (single dose x 7 days) was co-administered with 200 mg ketoconazole, a strong CYP3A4 inhibitor or ketoconazole placebo twice daily for 11 days and the pharmacokinetics of buprenorphine and its metabolites were evaluated.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      However, certain protease inhibitors (PIs) with CYP3A4 inhibitory activity such as atazanavir and atazanavir/ritonavir resulted in elevated levels of buprenorphine and norbuprenorphine when buprenorphine and naloxone were administered sublingually.
    3. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      It should be noted that atazanavir is both a CYP3A4 and UGT1A1 inhibitor.
    4. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      As such, the drug-drug interaction potential for buprenorphine with CYP3A4 inhibitors is likely to be dependent on the route of administration as well as the specificity of enzyme inhibition [see Drug Interactions ( 7 )].
    5. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Effect of CYP3A4 Inhibitors In a drug-drug interaction study, buprenorphine transdermal system 10 mcg/hour (single dose x 7 days) was co-administered with 200 mg ketoconazole, a strong CYP3A4 inhibitor or ketoconazole placebo twice daily for 11 days and the pharmacokinetics of buprenorphine and its metabolites were evaluated.
    6. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      However, certain protease inhibitors (PIs) with CYP3A4 inhibitory activity such as atazanavir and atazanavir/ritonavir resulted in elevated levels of buprenorphine and norbuprenorphine when buprenorphine and naloxone were administered sublingually.
    7. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      It should be noted that atazanavir is both a CYP3A4 and UGT1A1 inhibitor.
    8. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      As such, the drug-drug interaction potential for buprenorphine with CYP3A4 inhibitors is likely to be dependent on the route of administration as well as the specificity of enzyme inhibition [see Drug Interactions ( 7 )].
    9. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Based on the results from this study, metabolism during therapy with buprenorphine transdermal system is not expected to be affected by co-administration of CYP3A4 inhibitors [see Drug Interactions ( 7 )].
    10. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Based on the results from this study, metabolism during therapy with buprenorphine transdermal system is not expected to be affected by co-administration of CYP3A4 inhibitors [see Drug Interactions ( 7 )].

  4. Projected row 1054

    Medicine slug
    buprenorphine
    Medicine name
    Buprenorphine
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    6
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Buprenorphine primarily undergoes N -dealkylation by CYP3A4 to norbuprenorphine and glucuronidation by UGT-isoenzymes (mainly UGT1A1 and 2B7) to buprenorphine 3β- O -glucuronide.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Antiretroviral agents have been evaluated for CYP3A4 mediated interactions with sublingual buprenorphine.
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Effect of CYP3A4 Inducers The interaction between buprenorphine and CYP3A4 inducers has not been studied.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Buprenorphine primarily undergoes N -dealkylation by CYP3A4 to norbuprenorphine and glucuronidation by UGT-isoenzymes (mainly UGT1A1 and 2B7) to buprenorphine 3β- O -glucuronide.
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Antiretroviral agents have been evaluated for CYP3A4 mediated interactions with sublingual buprenorphine.
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)

      Buprenorphine label

      Version not recorded · Effective date not recorded

      Effect of CYP3A4 Inducers The interaction between buprenorphine and CYP3A4 inducers has not been studied.

  5. Projected row 1055

    Medicine slug
    bupropion
    Medicine name
    Bupropion
    Enzyme or transporter
    CYP2B6
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Inducers of CYP2B6 Ritonavir and Lopinavir: In a healthy volunteer study, ritonavir 100 mg twice daily reduced the AUC and C max of bupropion by 22% and 21%, respectively.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Inducers of CYP2B6 Ritonavir and Lopinavir: In a healthy volunteer study, ritonavir 100 mg twice daily reduced the AUC and C max of bupropion by 22% and 21%, respectively.

  6. Projected row 1056

    Medicine slug
    bupropion
    Medicine name
    Bupropion
    Enzyme or transporter
    CYP2B6
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Inhibitors of CYP2B6 Ticlopidine and Clopidogrel: In a study in healthy male volunteers, clopidogrel 75 mg once daily or ticlopidine 250 mg twice daily increased exposures (C max and AUC) of bupropion by 40% and 60% for clopidogrel, by 38% and 85% for ticlopidine, respectively.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Inhibitors of CYP2B6 Ticlopidine and Clopidogrel: In a study in healthy male volunteers, clopidogrel 75 mg once daily or ticlopidine 250 mg twice daily increased exposures (C max and AUC) of bupropion by 40% and 60% for clopidogrel, by 38% and 85% for ticlopidine, respectively.

  7. Projected row 1057

    Medicine slug
    bupropion
    Medicine name
    Bupropion
    Enzyme or transporter
    CYP2B6
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    6
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Drug Interactions Potential for Other Drugs to Affect Bupropion Hydrochloride Extended-Release Tablets (XL) In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by CYP2B6.
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Therefore, the potential exists for drug interactions between bupropion hydrochloride extended-release tablets (XL) and drugs that are inhibitors or inducers of CYP2B6.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion.
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Drug Interactions Potential for Other Drugs to Affect Bupropion Hydrochloride Extended-Release Tablets (XL) In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by CYP2B6.
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Therefore, the potential exists for drug interactions between bupropion hydrochloride extended-release tablets (XL) and drugs that are inhibitors or inducers of CYP2B6.

  8. Projected row 1058

    Medicine slug
    bupropion
    Medicine name
    Bupropion
    Enzyme or transporter
    CYP2D6
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Drugs Metabolized by CYP2D6 In vitro , bupropion and hydroxybupropion are CYP2D6 inhibitors.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Drugs Metabolized by CYP2D6 In vitro , bupropion and hydroxybupropion are CYP2D6 inhibitors.

  9. Projected row 1059

    Medicine slug
    bupropion
    Medicine name
    Bupropion
    Enzyme or transporter
    CYP2D6
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    6
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      In a clinical study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of CYP2D6, bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the C max , AUC, and T 1/2 of desipramine by an average of approximately 2- , 5-, and 2-fold, respectively.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Citalopram: Although citalopram is not primarily metabolized by CYP2D6, in one study bupropion increased the C max and AUC of citalopram by 30% and 40%, respectively.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      In a clinical study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of CYP2D6, bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the C max , AUC, and T 1/2 of desipramine by an average of approximately 2- , 5-, and 2-fold, respectively.
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

      Bupropion label

      Version not recorded · Effective date not recorded

      Citalopram: Although citalopram is not primarily metabolized by CYP2D6, in one study bupropion increased the C max and AUC of citalopram by 30% and 40%, respectively.

  10. Projected row 1060

    Medicine slug
    buspirone
    Medicine name
    Buspirone
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    1
    Complete sentence records
    1. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:9a702362-39cb-4171-8d64-f37fa7e1f638 (opens source in a new tab)

      Buspirone label

      Version not recorded · Effective date not recorded

      Buspirone is metabolized primarily by oxidation, which in vitro has been shown to be mediated by cytochrome P450 3A4 (CYP3A4) (see PRECAUTIONS , Drug Interactions ).

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=1050

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy